We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
An editorial update: what level of blood pressure control in chronic kidney disease?
- Authors
Levey, Andrew S.; Mulrow, Cynthia D.
- Abstract
The article presents information on the Ramipril Efficacy in Nephropathy 2 (REIN-2) Trial. The REIN-2 Trial, a multicenter, randomized, controlled, nonblinded superiority trial, included patients with nondiabetic kidney disease, proteinuria, and decreased glomerular filtration rate. Participants were randomly assigned to either a lower or usual blood pressure goal and received the ACE inhibitor ramipril. The REIN-2 Trial showed that adding felodipine, an agent that does not directly inhibit the renin-angiotensin system, to ramipril and other antihypertensive agents can reduce blood pressure, but probably does not have a large effect in slowing the progression of kidney disease during short-term follow-up.
- Subjects
CLINICAL trials; KIDNEY diseases; ACE inhibitors; BLOOD pressure; KIDNEY glomerulus; ANTIHYPERTENSIVE agents
- Publication
Annals of Internal Medicine, 2005, Vol 143, Issue 1, p79
- ISSN
0003-4819
- Publication type
editorial
- DOI
10.7326/0003-4819-143-1-200507050-00013